Barclays PLC Grows Stock Holdings in Qiagen (NYSE:QGEN)

by · The Markets Daily

Barclays PLC grew its holdings in Qiagen (NYSE:QGEN – Free Report) by 170.6% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,849,004 shares of the company’s stock after buying an additional 1,165,594 shares during the period. Barclays PLC’s holdings in Qiagen were worth $84,259,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. GAMMA Investing LLC raised its holdings in Qiagen by 806.5% during the 3rd quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock valued at $26,000 after buying an additional 500 shares during the period. Toronto Dominion Bank purchased a new stake in shares of Qiagen in the second quarter valued at $27,000. Massmutual Trust Co. FSB ADV lifted its holdings in shares of Qiagen by 39.8% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock worth $39,000 after acquiring an additional 243 shares during the last quarter. CWM LLC lifted its holdings in shares of Qiagen by 12.0% in the 2nd quarter. CWM LLC now owns 2,505 shares of the company’s stock worth $103,000 after acquiring an additional 269 shares during the last quarter. Finally, Headlands Technologies LLC boosted its stake in shares of Qiagen by 396.6% during the 2nd quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock worth $113,000 after purchasing an additional 2,189 shares during the period. 70.00% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

QGEN has been the subject of several analyst reports. HSBC downgraded shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective for the company. in a research note on Thursday, October 17th. Jefferies Financial Group reissued a “buy” rating and set a $54.00 price target (up from $42.00) on shares of Qiagen in a research note on Tuesday. Finally, Hsbc Global Res raised Qiagen to a “hold” rating in a research report on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Qiagen has an average rating of “Moderate Buy” and a consensus price target of $51.15.

View Our Latest Report on Qiagen

Qiagen Trading Up 0.2 %

Shares of NYSE QGEN opened at $46.16 on Thursday. Qiagen has a twelve month low of $39.03 and a twelve month high of $47.44. The firm has a market cap of $10.53 billion, a PE ratio of 118.36, a price-to-earnings-growth ratio of 3.37 and a beta of 0.35. The business has a fifty day simple moving average of $43.13 and a two-hundred day simple moving average of $43.68. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39.

Qiagen Profile

(Free Report)

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.

Featured Stories

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen (NYSE:QGEN – Free Report).